Genedata Announces Partnership with Dragonfly Therapeutics to Support Novel Immune Engager R&D
Genedata Biologics supports R&D processes at innovative biopharmaceutical company developing breakthrough immunotherapies for the treatment of cancer and chronic inflammatory diseases
July 13, 2023
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Dragonfly Therapeutics, a clinical-stage biotechnology company developing novel immunotherapies, is using the Genedata Biologics® integrated R&D workflow platform. The platform supports Dragonfly’s development of novel multi-specific therapies designed as natural combinations harnessing NK cells, γδ T cells, CD8+ T cells, and other cells of the innate and adaptive immune system, to provide a unique therapeutic window beyond current therapies for treatment of cancer and chronic inflammatory diseases. “We selected Genedata Biologics because of its unique workflow and registration engine that supports processes from candidate selection all the way through IND filings and commercialization,” said Ann Cheung, Ph.D., Head of Research at Dragonfly Therapeutics. “It was important to us to put workflows in place that can give us out-of-the-box support for our novel R&D programs. Genedata has an excellent reputation and notable ability to develop innovative digital solutions that are purpose-built for biotherapeutic R&D.”
Genedata Biologics is a first-in-class workflow system that streamlines discovery of biotherapeutics of any format, including bi- and multi-specifics, adoptive cell therapies, gene therapies, and RNA. Uniquely designed from the start to digitalize biotherapeutic discovery, the platform facilitates and automates complex R&D processes. Genedata Biologics acts as a central end-to-end data backbone that integrates all R&D processes from molecular biology, screening, engineering, expression, purification, and analytics, to candidate developability and manufacturability assessments. Real-time access to all data enables users at all levels of an organization to rapidly make more informed decisions, as well as to analyze data patterns that drive future discovery programs.
“By providing Dragonfly Therapeutics with a central data backbone for their discovery pipeline, we are making their R&D faster and more efficient,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Our technology, combined with Dragonfly’s unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives.”
Since its first release in 2011, Genedata Biologics has been rapidly adopted by most of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and rollout and deployment support.
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
LinkedIn | Twitter
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.